Banks are getting ready to submit final offers to Brookfield Asset Management for a debt package of about €11 billion ($11.6 ...

Mason Capital opposes Grifols sale to Brookfield Asset Management, raising concerns about the potential acquisition in the ...

Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of ...

MADRID (Reuters) -Spanish drugmaker Grifols said on Thursday it was on track to meet its targets for the year after its net ...

This includes revenues from technology disclosure and from development services for Grifols, S.A. Previously, an increase in the high single-digit percentage range had been expected. The return on ...

Brookfield Asset Management is awaiting information from Grifols SA about related-party transactions as it seeks to complete ...

Deutsche Bank raised the firm’s price target on Grifols (GRFS) to EUR 10 from EUR 9 and keeps a Hold rating on the shares. Published first on TheFly – the ultimate source for real-time, market-moving ...

Grifols (NASDAQ:GRFS) holder Mason Capital said it's against a potential sale of the Spanish drugmaker to Brookfield Asset Management (BAM). Mason Capital, which has a 2.1% stake in Grifols (GRFS ...

Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged14-Nov-2024 / 08:56 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division. Shares traded 4.7% higher ...